Replies to post #22945 on RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

Neuro, what's your take on the timing of this CX1739, Cor's decision to pursue sleep apnea with CX1739 as opposed to ADHD, the trial's date to begin in 2-09 with respect to the thesis that a RD deal is nearing signing around month's end, or a 10 million dollar financing is nearing signing around month's end. It was always my understanding that CX1739 wasn't going to necessarily be included in an RD deal to begin with.